Selective FFA2 agonism appears to act via intestinal PYY to reduce transit and food intake but does not improve glucose tolerance in mouse models

Diabetes

Volumn 64, Issue 11, 2015, Pages 3763-3771

  Forbes, Sarah ^a   Stafford, Stuart ^b   Coope, Gareth ^b   Heffron, Helen ^b   Real, Katia ^b   Newman, Robert ^b   Davenport, Richard ^b   Barnes, Matt ^b   Grosse, Johannes ^b   Cox, Helen ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Takeda Pharmaceuticals Cambridge Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 CHLOROPHENYL) 1 1 [2' METHOXY(1,1' BIPHENYL) 4 CARBONYL]PYRROLIDINE 2 CARBOXYLIC ACID; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; DIPEPTIDYL PEPTIDASE IV; FREE FATTY ACID RECEPTOR 2; GLUCAGON LIKE PEPTIDE 1; INSULIN; PEPTIDE YY; RECEPTOR; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; FREE FATTY ACID 2 RECEPTOR, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FOOD INTAKE; GLUCOSE TOLERANCE; HORMONE RELEASE; IMPAIRED GLUCOSE TOLERANCE; IN VIVO STUDY; INSULIN BLOOD LEVEL; INTESTINE MUCOSA; INTESTINE TRANSIT TIME; ION TRANSPORT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION; AGONISTS; ANIMAL; APPETITE; CELL CULTURE; DRUG EFFECTS; EATING; GASTROINTESTINAL TRANSIT; GLUCOSE INTOLERANCE; INTESTINE; METABOLISM; MOUSE MUTANT; OBESITY; PHYSIOLOGY;

ANIMALS; APPETITE; CELLS, CULTURED; EATING; GASTROINTESTINAL TRANSIT; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; INTESTINES; MICE; MICE, OBESE; OBESITY; PEPTIDE YY; RECEPTORS, CELL SURFACE;

EID: 84952338130     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0481     Document Type: Article

References (47)

1. Schauer PR, Bhatt DL, Kirwan JP, et al.; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med 2014;370:2002-2013
2. Schwiertz A, Taras D, Schäfer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2010;18:190-195
3. Sleeth ML, Thompson EL, Ford HE, Zac-Varghese SEK, Frost G. Free fatty acid receptor 2 and nutrient sensing: a proposed role for fibre, fermentable carbohydrates and short-chain fatty acids in appetite regulation. Nutr Res Rev 2010;23:135-145
4. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science 2012;336:1262-1267
5. Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 2009;106:2365-2370
6. Liou AP, Paziuk M, Luevano J-M Jr, Machineni S, Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 2013;5:178ra41
7. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 2001;81:1031-1064
8. Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003;278:11312-11319
9. Le Poul E, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003;278:25481-25489
10. Karaki S, Mitsui R, Hayashi H, et al. Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell Tissue Res 2006;324:353-360
11. Karaki S-I, Tazoe H, Kaji I, Otomo Y, Yajima T, Kuwahara A. Contractile and secretory responses of luminal short-chain fatty acids and the expression of these receptors, GPR41 and GPR43, in the human small and large intestines. Gastroenterology 2008;134:A368
12. Symonds EL, Young RL, Page AJ, Li H, Blackshaw LA. Nutrient Sensing Receptors Are Regionally Expressed Throughout the Gastrointestinal Tract and Modulated by a High Fat Diet in Mice. Gastroenterology 2011;140:S334
13. Holst JJ. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr Opin Pharmacol 2013;13:983-988
14. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012;61:364-371
15. Kimura I, Ozawa K, Inoue D, et al. The gut microbiota suppresses insulinmediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 2013;4:1829
16. Mace OJ, Schindler M, Patel S. The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CasR in rat small intestine. J Physiol 2012;590:2917-2936
17. Psichas A, Sleeth ML, Murphy KG, et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes 2015;39:424-429
18. Freeland KR, Wolever TMS. Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-alpha. Br J Nutr 2010;103:460-466
19. Dirksen C, Hansen DL, Madsbad S, et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care 2010;33:375-377
20. Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987;28:166-170
21. 2 receptors. Br J Pharmacol 2011;164:471-484
22. Ekblad E, Sundler F. Distribution of pancreatic polypeptide and peptide YY. Peptides 2002;23:251-261
23. Cox HM. Neuropeptide Y receptors; antisecretory control of intestinal epithelial function. Auton Neurosci 2007;133:76-85
24. Chandarana K, Gelegen C, Irvine EE, et al. Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance. Mol Metab 2013;2:142-152
25. Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 2007;292:E1062-E1068
26. Zac-Varghese S, De Silva A, Bloom SR. Translational studies on PYY as a novel target in obesity. Curr Opin Pharmacol 2011;11:582-585
27. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003;114:115-121
28. Burcelin R, Gourdy P, Dalle S. GLP-1-based strategies: a physiological analysis of differential mode of action. Physiology (Bethesda) 2014;29:108-121
29. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009;23:463-477
30. Kim MH, Kang SG, Park JH, Yanagisawa M, Kim CH. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology 2013;145:396-406. e1, 10
31. Bindels LB, Dewulf EM, Delzenne NM. GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci 2013;34:226-232
32. Tang C, Ahmed K, Gille A, et al. Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nat Med 2015;21:173-177
33. Hudson BD, Due-Hansen ME, Christiansen E, et al. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem 2013;288:17296-17312
34. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab 2008;8:532-539
35. Cox HM, Tough IR, Woolston A-M, et al. Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses. Cell Metab 2010;11:532-542
36. Forbes S, Herzog H, Cox HM. A role for neuropeptide Y in the genderspecific gastrointestinal, corticosterone and feeding responses to stress. Br J Pharmacol 2012;166:2307-2316
37. Cho H-J, Robinson ES, Rivera LR, et al. Glucagon-like peptide 1 and peptide YY are in separate storage organelles in enteroendocrine cells. Cell Tissue Res 2014;357:63-69
38. Chambers ES, Viardot A, Psichas A, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 10 December 2014 [Epub ahead of print]. DOI: 10.1136/gutjnl-2014-307913
39. Plaisancié P, Dumoulin V, Chayvialle JA, Cuber JC. Luminal glucagon-like peptide-1 (7-36) amide-releasing factors in the isolated vascularly perfused rat colon. J Endocrinol 1995;145:521-526
40. Plaisancié P, Dumoulin V, Chayvialle JA, Cuber JC. Luminal peptide YYreleasing factors in the isolated vascularly perfused rat colon. J Endocrinol 1996;151:421-429
41. Anini Y, Fu-Cheng X, Cuber JC, Kervran A, Chariot J, Roz C. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflugers Arch 1999;438:299-306
42. Gerspach AC, Steinert RE, Schönenberger L, Graber-Maier A, Beglinger C. The role of the gut sweet taste receptor in regulating GLP-1, PYY, and CCK release in humans. Am J Physiol Endocrinol Metab 2011;301:E317-E325
43. Cox HM, Cuthbert AW, Håkanson R, Wahlestedt C. The effect of neuropeptide Y and peptide YY on electrogenic ion transport in rat intestinal epithelia. J Physiol 1988;398:65-80
44. Panaro BL, Tough IR, Engelstoft MS, et al. The melanocortin-4 receptor is expressed in enteroendocrine L cells and regulates the release of peptide YY and glucagon-like peptide 1 in vivo. Cell Metab 2014;20:1018-1029
45. Forbes SC, Cox HM. Peptide YY, neuropeptide Y and corticotrophin-releasing factor modulate gastrointestinal motility and food intake during acute stress. Neurogastroenterol Motil 2014;26:1605-1614
46. Wang L, Gourcerol G, Yuan P-Q, et al. Peripheral peptide YY inhibits propulsive colonic motor function through Y2 receptor in conscious mice. Am J Physiol Gastrointest Liver Physiol 2010;298:G45-G56
47. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY (3-36) physiologically inhibits food intake. Nature 2002;418:650-654